Skip to main content

Table 1 Baseline and clinicopathological characteristics in relation to CAR with cut-off at 0.2. Percentages represent proportion within group

From: The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection

  Total
n = 163
CAR < 0.2
n = 90 (55%)
CAR ≥ 0.2
n = 73 (45%)
P value
Sex     0.875
 Male 87 49 (56%) 38 (44%)  
 Female 76 41(54%) 35 (46%)  
Age, years (mean, SD) 66 (± 9.7) 65 (± 9.7) 67 (± 9.7) 0.591
ASA     0.055
 I 12 7 (58%) 5 (42%)  
 II 121 73 (60%) 48 (40%)  
 III 29 10 (34%) 19 (66%)  
 IV 1 0 (0%) 1 (100%)  
ECOG grade 11 unknown 45 (59%) 31 (41%) 0.380
 0 76 29 (52%) 27 (48%)  
 1 56 7 (50%) 7 (50%)  
 2 14 1 (20%) 4 (80%)  
 3 5 1 (100%) 0 (0%)  
 4 1    
Haemoglobin, g/dL (mean, SD) 12.9 (± 1.6) 13.4 (± 1.5) 12.1 (± 1.6) < 0.001
CEA, ng/ml (median, IQR) 4.1 (2.2–6.7) 4.5 (2.2–6.6) 3.2 (2.2–7.5) 0.577
CA 19-9, U/ml (median, IQR) 246 (60–936) 342 (54–867) 133 (62–1092) 0.800
Supplementary nutrition 38 unknown    
 No 61 39 (64%) 22 (36%) 0.398
 Enteral 57 31 (54%) 26 (46%)  
 Parenteral 7 3 (43%) 4 (57%)  
Neoadjuvant therapy     0.692
 No 157 86 (55%) 71 (45%)  
 Yes 6 4 (67%) 2 (33%)  
Approach
 Open or conversion 154 85 (55%) 69 (45%) 1.000
 Laparoscopy 9 5 (56%) 4 (44%)  
Type of resection
 PPPD 106 59 (56%) 47 (44%) 0.043a
 PD (Whipple’s) 24 9 (37%) 15 (63%)  
 Distal pancreas resection 22 17 (77%) 5 (23%)  
 Central pancreas resection 2 0 (0%) 2 (100%)  
 Total pancreatectomy 9 5 (56%) 4 (44%)  
Complication
 Clavien–Dindo 0–2 137 76 (55%) 61 (45%) 1.000
 Clavien–Dindo 3–5 26 14 (54%) 12 (46%)  
Tumour size in mm (median, IQR) 30 (25–40) 30 (25–40) 35 (25–40) 0.477
Differentiation grade 25 unknown    
 Well or moderate 88 49 (56%) 39 (44%) 0.861
 Poorly 50 27 (54%) 23 (46%)  
Metastatic lymph nodes
 < 5 108 64 (59%) 44 (41%) 0.183
 ≥ 5 55 26 (47%) 29 (53%)  
Metastatic lymph node ratio 0.16 (0.06–0.26) 0.13 (0.04–0.25) 0.19 (0.01–0.29) 0.007
Metastatic lymph node ratio
 0 36 24 (67%) 12 (33%) 0.005
 < 0.10 26 20 (77%) 6 (23%)  
 ≥ 0.10 101 46 (45%) 55 (55%)  
Para-aortic lymph node
 No metastasis 152 85 (56%) 67 (44%) 0.543
 One or more metastases 11 5 (45%) 6 (55%)  
Radicality 2 unknown    
 R0 94 53 (56%) 41 (44%) 0.726
 R1 64 35 (55%) 39 (45%)  
 R2 3 1 (33%) 2 (67%)  
Adjuvant therapy 5 unknown    
 No 56 28 (50%) 28 (50%) 0.246
 Yes 102 61 (60%) 41 (40%)  
  1. ASA American Society of Anesthesiologists, ECOG Eastern Cooperative Oncology Group scale of performance, CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, PPPD pylorus-preserving pancreatoduodenectomy, PD pancreatoduodenectomy, SD standard deviation, IQR interquartile range
  2. apancreatoduodenectomy vs. other pancreas resections: p = 0.171